CN118450892A - 缝隙连接调节剂及其用于治疗年龄相关性黄斑变性的用途 - Google Patents

缝隙连接调节剂及其用于治疗年龄相关性黄斑变性的用途 Download PDF

Info

Publication number
CN118450892A
CN118450892A CN202280084727.5A CN202280084727A CN118450892A CN 118450892 A CN118450892 A CN 118450892A CN 202280084727 A CN202280084727 A CN 202280084727A CN 118450892 A CN118450892 A CN 118450892A
Authority
CN
China
Prior art keywords
compound
treatment
amd
prevention according
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280084727.5A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔里克·莫里岑
布拉德福德·扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Breyer Therapy Co ltd
Original Assignee
Breyer Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breyer Therapy Co ltd filed Critical Breyer Therapy Co ltd
Publication of CN118450892A publication Critical patent/CN118450892A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280084727.5A 2021-12-22 2022-12-21 缝隙连接调节剂及其用于治疗年龄相关性黄斑变性的用途 Pending CN118450892A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163292783P 2021-12-22 2021-12-22
US63/292,783 2021-12-22
PCT/EP2022/087342 WO2023118366A1 (en) 2021-12-22 2022-12-21 Gap junction modulators and their use for the treatment of age-related macular degeneration

Publications (1)

Publication Number Publication Date
CN118450892A true CN118450892A (zh) 2024-08-06

Family

ID=84981302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280084727.5A Pending CN118450892A (zh) 2021-12-22 2022-12-21 缝隙连接调节剂及其用于治疗年龄相关性黄斑变性的用途

Country Status (9)

Country Link
US (1) US20250018002A1 (https=)
EP (1) EP4452260B1 (https=)
JP (1) JP2025500123A (https=)
CN (1) CN118450892A (https=)
CA (1) CA3240515A1 (https=)
DK (1) DK4452260T3 (https=)
FI (1) FI4452260T3 (https=)
IL (1) IL313729A (https=)
WO (1) WO2023118366A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202310195D0 (en) * 2023-07-03 2023-08-16 Hastings Nataly Method for mitigating symptoms of neurological condition and a system therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6259296A (ja) 1985-09-10 1987-03-14 Green Cross Corp:The ペプタイド誘導体
IL157447A0 (en) 2001-02-22 2004-03-28 Zealand Pharma As Zealand Phar New medical uses of intercellular communication facilitating compounds
UA96283C2 (uk) 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
PL2468724T3 (pl) 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych
JP6989864B2 (ja) * 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用

Also Published As

Publication number Publication date
WO2023118366A1 (en) 2023-06-29
CA3240515A1 (en) 2023-06-29
US20250018002A1 (en) 2025-01-16
EP4452260B1 (en) 2026-01-28
EP4452260A1 (en) 2024-10-30
JP2025500123A (ja) 2025-01-09
IL313729A (en) 2024-08-01
FI4452260T3 (fi) 2026-03-30
DK4452260T3 (da) 2026-03-30

Similar Documents

Publication Publication Date Title
US10799552B2 (en) Methods for treating diabetic neurotherapy
CA2671613C (en) Methods of use of trk receptor modulators
Jutley et al. Management of glaucoma as a neurodegenerative disease
US11123411B2 (en) Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US20130137637A1 (en) Peptides for promoting angiogenesis and an use thereof
TW201412325A (zh) 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療
Xu et al. A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo
CA3130817A1 (en) Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
CN118450892A (zh) 缝隙连接调节剂及其用于治疗年龄相关性黄斑变性的用途
JP6989864B2 (ja) ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
US20230338483A1 (en) Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
EA051681B1 (ru) Модуляторы щелевых контактов и их применение для лечения возрастной макулярной дегенерации
JP7795359B2 (ja) 上皮および関門の完全性を保護するための組成物および方法
Lee et al. Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model
US11096993B2 (en) Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
HK1143544A (en) The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
Thakur Retinal delivery of steroidal and non-steroidal drugs for the treatment of back of the eye disorders
KR20050011350A (ko) 인간 인테그린 결합 단백질 또는 펩타이드를 유효성분으로하는 안질환 치료제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination